There are currently 28 active clinical trials seeking participants for Interstitial Lung Disease research studies. The states with the highest number of trials for Interstitial Lung Disease participants are California, Texas, Florida and New York.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: UAB Lung Health Center, Birmingham, Alabama +87 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: AnMed Health, Anderson, South Carolina +1 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Pulmonary Hypertension SOLAR
Recruiting
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Pulmonary Associates, Phoenix, Arizona +38 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Recruiting
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Mayo Clinic - Scottsdale ( Site 4014), Phoenix, Arizona +85 locations
Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/17/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +105 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Recruiting
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
10/09/2024
Locations: University of California, San Francisco, San Francisco, California +5 locations
Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
A Study of Mosliciguat in PH-ILD
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/09/2024
Locations: PulmonIx, Greensboro, North Carolina +1 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interstitial Lung Disease Research Unit Biobank
Recruiting
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Pulmonary Fibrosis Foundation Community Registry
Recruiting
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Pulmonary Fibrosis Foundation, Chicago, Illinois
Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +13 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/26/2024
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension